小分子疗法治疗儿科炎性肠病:走向精准医学
Ying Chen1, Yang Wang1, Jing Guo1
1Department of Pediatric Gastroenterology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, China.
像JAK抑制剂这样的小分子药物在儿科炎性肠病 (pIBD) 中表现有前途,但长期的安全性和发育效应需要进一步研究. 针对年龄的试验对于优化治疗至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 儿科胃肠病学 儿科胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿科炎症性肠病 (pIBD) 提出了独特的挑战,包括快速进展,生长障碍和发育迟缓.
- 有效的治疗必须同时解决肠道炎症和儿童的整体发育需求.
研究的目的:
- 审查目前小分子治疗pIBD的进展.
- 作为关键研究领域,重点关注Janus 激酶 (JAK) 抑制剂和氨酸-1-酸盐 (S1P) 调节剂.
主要方法:
- 临床试验,现实研究和机械学调查的系统审查.
- 在PubMed的文献搜索和临床试验注册表.
- 重点是JAK抑制剂和S1P调节剂.
主要成果:
- 托法西提尼布和乌帕达西提尼布 (JAK抑制剂) 在耐药儿科IBD中表现出有效性,但由于安全问题 (感染,发育,恶性瘤,心血管事件) 而非标签使用.
- 奥萨尼莫德 (S1P调节器) 正在儿童临床评估中,但长期数据有限.
- 新兴技术揭示了依赖年龄的免疫重塑,突出了对发育相关治疗的需求.
结论:
- 小分子疗法为pIBD提供了精确的治疗选择.
- 未来的进展需要针对特定年龄的试验,药理动力学建模和多组生物标志物的发现.
- 合作研究对于优化儿科患者的安全性和疗效至关重要.
更多相关视频
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Microorganisms in Medicine and Therapeutics
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
